Parathyroid hormone in the treatment of osteoporosis

Manuel Sosa Henríquez, A. Díez Pérez

Research output: Contribution to journalReview articleResearchpeer-review

7 Citations (Scopus)


Current treatments available for osteoporosis until recently were active by inhibiting osteoclast activity and, thus, reducing bone remodelling. Intact PTH (PTH 1-84) and its analog, teriparatida (human recombinant PTH 1-34), are a new class of anabolic treatment of osteoporosis. It has been described a positive effect on bone microarchitecture and a reduction of the risk of new fractures due to a bone-forming mechanism. PTH must be considered as an useful alternative in the treatment of severe osteoporosis, both in men and women, in patients with several osteoporosis-related fractures or with a very low bone mineral density (T-score below -3.5) an a high risk for fracture. Other potential uses are glucocorticoid-induced and other secondary osteoporosis. The use of PTH is not recommended for more than 18 months for teriparatida and 24 months for PTH 1-84. Copyright © 2007 Aran Ediciones, s.l.
Original languageEnglish
Pages (from-to)87-97
JournalAnales de Medicina Interna
Issue number2
Publication statusPublished - 1 Feb 2007


  • Anabolic
  • Bone mineral density
  • Fracture
  • Osteoporosis
  • Postmenopausal
  • PTH
  • Risk
  • Treatment
  • Women


Dive into the research topics of 'Parathyroid hormone in the treatment of osteoporosis'. Together they form a unique fingerprint.

Cite this